Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Hydrochloride, Nafoxidine
2. Nafoxidine Hydrochloride
3. U 11,100a
4. U 11000a
5. U-11,100a
6. U-11000a
7. U11,100a
8. U11000a
1. 1845-11-0
2. Nafoxidine [inn]
3. Nafoxidinum [inn-latin]
4. Nafoxidina [inn-spanish]
5. 1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine
6. U-11000a
7. Pyrrolidine, 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)-
8. Chembl28211
9. 4riy10wm82
10. Chebi:34881
11. Nsc 70735
12. 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)pyrrolidine
13. 1-(2-(4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy)ethyl)pyrrolidine
14. 1-{2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine
15. Pyrrolidine, 1-(2-(p-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy)ethyl)-
16. Pyrrolidine,1-[2-[4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy]ethyl]-
17. Nafoxidina
18. Nafoxidinum
19. Nsc70735
20. Brn 1440873
21. Unii-4riy10wm82
22. Spectrum5_000222
23. Nafoxidine [who-dd]
24. 5-20-01-00210 (beilstein Handbook Reference)
25. Bidd:er0063
26. Schembl153125
27. 11100a (*hydrochloride*)
28. Gtpl4263
29. Dtxsid7022386
30. U 11100 (*hydrochloride*)
31. U 11100a (*hydrochloride*)
32. U-11100a (*hydrochloride*)
33. Zinc538045
34. Bdbm50065941
35. Ncgc00188970-01
36. 845n110
37. Q6958201
38. 1-(2-(4-(3,4-dihydro-6-methoxy-2-phenyl-1-naphthalenyl)phenoxy)ethyl)pyrrolidine
39. 1-(2-[4-(6-methoxy-2-phenyl-3,4-dihydro-1-naphthalenyl)phenoxy]ethyl)pyrrolidine #
40. 1-{2-[4-(6-methoxy-2-phenyl-3,4-dihydro-naphthalen-1-yl)-phenoxy]-ethyl}-pyrrolidine
Molecular Weight | 425.6 g/mol |
---|---|
Molecular Formula | C29H31NO2 |
XLogP3 | 5.8 |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 7 |
Exact Mass | 425.235479232 g/mol |
Monoisotopic Mass | 425.235479232 g/mol |
Topological Polar Surface Area | 21.7 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 611 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Antineoplastic Agents, Hormonal
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079) (See all compounds classified as Antineoplastic Agents, Hormonal.)
Estrogen Antagonists
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds. (See all compounds classified as Estrogen Antagonists.)
ABOUT THIS PAGE
A Nafoxidine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Nafoxidine, including repackagers and relabelers. The FDA regulates Nafoxidine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Nafoxidine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Nafoxidine supplier is an individual or a company that provides Nafoxidine active pharmaceutical ingredient (API) or Nafoxidine finished formulations upon request. The Nafoxidine suppliers may include Nafoxidine API manufacturers, exporters, distributors and traders.
Nafoxidine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Nafoxidine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Nafoxidine GMP manufacturer or Nafoxidine GMP API supplier for your needs.
A Nafoxidine CoA (Certificate of Analysis) is a formal document that attests to Nafoxidine's compliance with Nafoxidine specifications and serves as a tool for batch-level quality control.
Nafoxidine CoA mostly includes findings from lab analyses of a specific batch. For each Nafoxidine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Nafoxidine may be tested according to a variety of international standards, such as European Pharmacopoeia (Nafoxidine EP), Nafoxidine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Nafoxidine USP).
LOOKING FOR A SUPPLIER?